Nectar Lifesciences Ltd
NECLIFENectar Lifesciences Ltd
NECLIFE
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 91.09 | 0.91 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.92 | 6.65 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Nectar Lifesciences Limited is a pharmaceutical company. The Company's operations include manufacturing and marketing of oral and sterile cephalosporin's, phytochemicals and allied products.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,681.46 | 1,666.37 | 1,882.29 | 2,788.91 | 2,370.70 | 1,547.08 | 1,680.15 | 1,566.85 | 1,698.66 | 1,684.13 | ||||||||||
Raw Materials | 1,198.70 | 1,145.85 | 1,417.32 | 2,268.13 | 1,862.83 | 1,052.82 | 1,207.32 | 1,200.84 | 1,242.45 | 1,507.11 | ||||||||||
| Power & Fuel Cost | 87.89 | 75.44 | 91.85 | 103.47 | 92.72 | 84.63 | 101.41 | 127.39 | 129.52 | |||||||||||
| Employee Cost | 78.38 | 75.54 | 74.65 | 76.54 | 78.19 | 70.59 | 71.91 | 75.14 | 81.71 | |||||||||||
| Selling & Administrative Expenses | 56.54 | 59.98 | 52.23 | 67.99 | 67.01 | 72.04 | 66.86 | 62.64 | 61.39 | |||||||||||
| Operating & Other expenses | 15.44 | 62.48 | 4.06 | 2.56 | 45.89 | 179.49 | 62.79 | 4.66 | 17.46 | |||||||||||
EBITDA | 244.51 | 247.08 | 242.18 | 270.22 | 224.06 | 87.51 | 169.86 | 96.18 | 166.13 | 177.02 | ||||||||||
| Depreciation/Amortization | 57.39 | 62.25 | 64.31 | 63.26 | 60.77 | 60.25 | 56.97 | 59.12 | 60.72 | 61.08 | ||||||||||
| PBIT | 187.12 | 184.83 | 177.87 | 206.96 | 163.29 | 27.26 | 112.89 | 37.06 | 105.41 | 115.94 | ||||||||||
| Interest & Other Items | 123.31 | 117.41 | 115.20 | 148.14 | 125.83 | 112.04 | 78.81 | 79.49 | 87.14 | 88.79 | ||||||||||
| PBT | 63.81 | 67.42 | 62.67 | 58.82 | 37.46 | -84.78 | 34.08 | -42.43 | 18.27 | 27.15 | ||||||||||
| Taxes & Other Items | 9.59 | 12.08 | 10.41 | 11.22 | 5.68 | -11.50 | 9.03 | -18.24 | 13.28 | 16.43 | ||||||||||
| Net Income | 54.22 | 55.34 | 52.26 | 47.60 | 31.78 | -73.28 | 25.05 | -24.19 | 4.99 | 10.72 | ||||||||||
| EPS | 2.42 | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | 0.48 | ||||||||||
| DPS | 0.10 | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.04 | 0.02 | 0.02 | 0.02 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Nectar Lifesciences Ltd | 195.68 | 0.91 | — |
| Sun Pharmaceutical Industries Ltd | 45.12 | 6.44 | 0.75% |
| Cipla Ltd | 28.85 | 4.44 | 0.88% |
| Torrent Pharmaceuticals Ltd | 69.10 | 16.69 | 0.83% |
Price Comparison
Compare NECLIFE with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 11.45%
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 1.31%
Decreased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has decreased by 14.03%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 11, 2020
Dividend/Share
₹0.05
Ex DateEx Date
Sep 11, 2020
Cash Dividend
Ex DateEx DateSep 19, 2019
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2019
Cash Dividend
Ex DateEx DateSep 19, 2018
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2018
Cash Dividend
Ex DateEx DateSep 20, 2017
Dividend/Share
₹0.05
Ex DateEx Date
Sep 20, 2017
Cash Dividend
Ex DateEx DateSep 22, 2016
Dividend/Share
₹0.10
Ex DateEx Date
Sep 22, 2016
Net profit of Nectar Lifescience rose 449.02% to Rs 5.60 crore in the quarter ended September 2024 as against Rs 1.02 crore during the previous quarter ended September 2023. Sales rose 7.52% to Rs 427.88 crore in the quarter ended September 2024 as against Rs 397.96 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales427.88397.96 8 OPM %10.136.75 - PBDT24.2116.95 43 PBT8.671.64 429 NP5.601.02 449 Powered by Capital Market - Live
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Nectar Lifescience announced that the Annual General Meeting (AGM) of the company will be held on 21 September 2024.Powered by Capital Market - Live
Nectar Lifescience announced that the Annual General Meeting (AGM) of the company will be held on 21 September 2024.Powered by Capital Market - Live
Net profit of Nectar Lifescience rose 63.19% to Rs 2.97 crore in the quarter ended June 2024 as against Rs 1.82 crore during the previous quarter ended June 2023. Sales declined 8.95% to Rs 358.85 crore in the quarter ended June 2024 as against Rs 394.12 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales358.85394.12 -9 OPM %11.099.02 - PBDT20.3818.39 11 PBT4.923.06 61 NP2.971.82 63 Powered by Capital Market - Live
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
Nectar Lifesciences stock ends 4.5% down after board nods sale of various assets to repay bank loans
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -9.44%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.27% to 0.45%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -36.31%, vs industry avg of 15.27%